Pluristem Therapeutics (PSTI) spikes on good news moving forward
Pluristem Therapeutics (PSTI) currently trades at $4.50 and has grown by 9.50% today. The recent spike from Pluristem is due to the reaction to preliminary data on the use of its PLX cells in severely ill COVID-19 patients in Israel. Seven ICU-housed patients with acute respiratory distress syndrome were treated under a compassionate use program. Six completed the seven-day follow-up period. Three are in advanced stages of weaning from ventilators and four have experienced improvements in respiratory parameters. One remains on a ventilator but is stable and one deteriorated.
Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article. The high forecast for Pluristem Therapeutics is $25.00 and the low is $8.00. Notably, the company’s market cap is $80.20 million with a 52 week high of $7.30 and a 52 week low of $2.82. PSTI went up to $0.39 from the previous closing price of $4.11. PSTI has changed in price by -1.38 per share in the last 12 months.
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, muscle injuries, hematological disorders and exposure to radiation. Their strategy is to develop powerful cell therapies that can be successfully commercialized to reach patients who need innovative treatment options. They develop placenta-derived, “off-the-shelf” products that do not require genetic or tissue matching prior to administration and could be delivered in almost any clinical setting.